Inelastic adjustable-strap below-knee gradient compression wrap with mechanical tension-calibration indicators, launched into the Medicare lymphedema compression benefit and coded to A6583 — business case

Intended use: For use by adults with a clinician-documented diagnosis of lower-extremity lymphedema, under the direction of a licensed clinician, to apply and maintain gradient compression to the below-knee limb during the maintenance (self-management) phase of complete decongestive therapy, in patients who are unable to self-don a flat-knit compression garment.

Who pays

The budget-holder chain has a benefit category and a payment formula written into federal regulation, and almost nothing else in it confirmed.

• Writes the cheque: Medicare Part B, through the DME MAC administering the lymphedema compression treatment items benefit, pays 80% of the lesser of the supplier's actual charge or a payment amount computed under a Medicaid/TRICARE/internet-retail-price methodology specific to this benefit category, for items furnished on or after 2024-01-01 [claim 43: verified]. The beneficiary owes the remaining 20% plus any unmet Part B deductible; the candidate's own restatement of this as a general "80% of the lesser of the actual charge or the DMEPOS fee schedule amount" is a separate, unconfirmed claim [claim 11: unconfirmed] that has never been checked against the item-specific formula above.
• Out of which budget line: the Medicare Part B lymphedema compression treatment items benefit category, created by 42 CFR 410.36(a)(4)(ii), which names "gradient compression wraps with adjustable straps" as one of three listed item types [claim 42: verified]. The category's statutory origin — the Lymphedema Treatment Act, said to be enacted in the Consolidated Appropriations Act, 2023 — is separately asserted and unconfirmed [claim 10: unconfirmed]; no connector in this repo reaches statute text, only CFR text.
• Against which comparator: the flat-knit garment, billed under adjacent codes A6552 ("gradient compression stocking, below knee, 30-40 mmHg, each") and A6554 ("below knee, 40 mmHg or greater, each") — asserted to exist in the same 2024 code set but never checked against a primary CMS source [claim 9: unconfirmed]. Whether the target patient population is currently billed under those codes at all, or goes uncompressed, is not established.
• Stops buying instead: not established anywhere in the file. The indication is defined by an inability to self-don the comparator garment [see intended use, above], so this may be additive spend against a population currently undertreated rather than substitution spend against the comparator's existing volume — but no claim in the file measures either reading, and the assumption that the failure to self-don a flat-knit garment is a documented clinical pattern rather than a marketing premise is itself only deck-sourced and unchecked [claim 26: unverified].

The chain's structural strength is also its structural gap. A benefit category and a payment formula naming this exact product type are verified primary text — a materially stronger starting position than most candidates in this pipeline reach. But the HCPCS code itself has never been confirmed to exist [claim 8: unconfirmed], no dollar figure has ever been read for it [claim 11: unconfirmed], and whether coverage is available for the diagnosis as broadly as assumed is unconfirmed [claim 12: unconfirmed]. A verified regulation naming the product category is not yet a priced, coded, covered pathway.

The money model

Decomposed, not asserted. Every line resolves to a copied claim or a declared assumption.

Read the strongest-looking figure first, and read past it. The 80%-of-lesser payment formula [claim 43: verified] and the benefit-category listing [claim 42: verified] are verified primary text — genuinely more than "a code exists." But every figure that would turn that formula into a dollar amount a manufacturer could plan against is unconfirmed: the code's own existence [claim 8: unconfirmed], its price [claim 11: unconfirmed], its coverage stance [claim 12: unconfirmed], and its billing frequency [claim 45: unconfirmed]. The composite that would answer "how big is this" cannot be built from what is on record.

The two connectors this repo reserves for exactly this shape of question both refuse, and the verdicts go on the page rather than being routed around:

• python3 -m connectors market "net selling price per below-knee gradient compression wrap bounded by the DMEPOS fee schedule allowable for A6583" → unverifiable — "Market-size claim ... has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report and edits the claim by hand." [claim 16: unconfirmed]
• python3 -m connectors adoption "certified lymphedema fitters and DMEPOS suppliers would stock and fit a new brand against four established ones" → unverifiable — "Adoption/preference claim ... needs primary research (interviews, survey, published preference study) ... Do NOT substitute a model's own estimate of stakeholder behaviour: a synthetic stakeholder opinion is a fabricated claim." [claim 24: unconfirmed]

Path to first revenue

• First dollar comes from: a DMEPOS supplier or certified fitter dispensing the wrap and billing Medicare Part B under A6583 for 80% of an allowable [claim 43: verified] whose dollar amount has never been read [claim 11: unconfirmed], plus a 20% coinsurance [claim 43: verified] collected from the beneficiary — all of it depending on the code existing as described at all [claim 8: unconfirmed].
• What must exist first, each attributed:
  • The membership question resolved in the exempt device's favor — whether FDA reads an inelastic strapped wrap into § 880.5780's "constructed of elastic material" identification, and whether § 880.9's lay-use provision fires on self-application without a fitter [claim 6: unconfirmed]. If this resolves the other way, first revenue is gated by a submission and a predicate, not by billing mechanics.
  • Establishment registration and device listing, and QMS compliance under the part-820 scope the exemption does not reach [claim 22: unconfirmed].
  • HCPCS A6583 confirmed to exist with a workable descriptor [claim 8: unconfirmed], [claim 44: unconfirmed], and a confirmed fee-schedule dollar amount [claim 11: unconfirmed].
  • PDAC coding-verification review, if one applies to a new manufacturer's product under this code, obtained without a clinical study or existing channel incumbency [claim 32: unverified], and confirmation the requirement exists at all [claim 14: unconfirmed].
  • DMEPOS supplier enrollment (CMS-855S) and coverage confirmed for the diagnosis as billed [claim 12: unconfirmed].
• Calendar to first dollar: not established — the candidate's own capital/time claim is deliberately stated without a month figure, and is itself conditional on the membership question above [claim 22: unconfirmed]. Whether the registration-to-first-claim turnaround is short enough to plan a launch against is [assumption A1].
• Capital to first dollar: not established — no dollar figure exists anywhere in the file [claim 22: unconfirmed]; whether the tooling, training and coding/enrollment spend is financeable within a launch-stage budget is [assumption A2].
• Whether the 20% coinsurance itself suppresses uptake at the point of dispensing is not established by any claim in the file, and is [assumption A3].

Routes

Four, laid out and not ranked. Choosing a commercial strategy is a Tier 3 act — the same class of decision as choosing what to shortlist — so this section presents options and stops.

Route A — Launch on the exempt reading, direct into the existing DMEPOS/certified-fitter channel under A6583

The route the candidate is built around: a device company manufacturing and selling the wrap into the existing lymphedema-compression dispensing channel, billed by DME suppliers and certified fitters under A6583 against the Part B benefit category.

• Requires: the § 880.5780 membership question resolved favorably [claim 6: unconfirmed]; HCPCS A6583 confirmed with a workable descriptor and dollar amount [claim 8: unconfirmed], [claim 44: unconfirmed], [claim 11: unconfirmed]; coverage confirmed for the diagnosis as billed [claim 12: unconfirmed]; and PDAC coding-verification obtained [claim 14: unconfirmed], [claim 32: unverified].
• Costs: on the exempt reading, registration/listing/QMS rather than a submission, with no dollar or month figure asserted anywhere in the file [claim 22: unconfirmed]; calendar and capital to a first billable claim are [assumption A1] and [assumption A2].
• Killed by: FDA determining that an inelastic strapped wrap does not fall within § 880.5780's "constructed of elastic material" identification, or that § 880.9's lay-use provision requires a premarket notification for self-application without a fitter — i.e. [claim 6: unconfirmed] resolving against the exempt reading. That converts this route from a launch into a submission with a different cost and calendar entirely.

Route B — License the tension-calibration indicator into an already-established incumbent wrap

Ship the differentiator, not the whole device: an OEM strap-tension-indicator module licensed into one of the four named incumbents' existing adjustable-wrap lines (medi circaid juxtafit/juxta-lite, Essity/BSN JOBST FarrowWrap, Sigvaris Compreflex, Solaris), all of which already occupy the certified-fitter and DMEPOS-supplier channel.

• Requires: an FTO position on the indicator clear enough to license — no patent search has been performed and no patent number is named anywhere in the file [claim 19: unconfirmed]; no unexpired blocking patent held by any of the four incumbents [claim 41: unverified]; and a partner willing to pay for the module rather than build an equivalent independently [claim 34: unverified] — [assumption A4].
• Costs: no independent DMEPOS enrollment, PDAC coding-verification, or channel build; regulatory-scoping and module-validation spend instead, against the same unstated capital baseline as Route A [claim 22: unconfirmed], [assumption A4].
• Killed by: an unexpired US patent held by one of the four named incumbents that already covers a strap-tension or elongation indicator on a limb compression wrap [claim 41: unverified] resolving false, or the incumbents choosing to develop an equivalent indicator in-house rather than license one — i.e. [claim 34: unverified] resolving false in the other direction, meaning they do respond.

Route C — Bypass Medicare billing; launch cash-pay / direct-to-consumer

Sell directly to patients and caregivers, or through non-DMEPOS retail channels, without relying on A6583 being billable at all — trading the reimbursement upside for independence from the PDAC/coding uncertainty above.

• Requires: the § 880.5780 membership question resolved favorably for labeling purposes regardless of billing route [claim 6: unconfirmed]; clinician willingness to recommend a device the patient pays for directly [claim 25: unconfirmed]; and patient/caregiver willingness to pay a price sustaining the channel — [assumption A5].
• Costs: no PDAC coding-verification or coverage-policy spend, but no coinsurance offset either, and likely materially smaller reachable volume than a billed pathway; capital and calendar otherwise track the unstated baseline in [claim 22: unconfirmed].
• Killed by: a pricing survey showing patients/caregivers will not pay materially more than the ~20% coinsurance a billed pathway through the existing DMEPOS channel would already leave them owing — [assumption A5] resolving false, once claim 11 or claim 43's dollar figure exists to benchmark against.

Route D — Buy down the membership risk directly: pursue a 513(g) or a formal premarket submission before commercial launch

Rather than launching on the exempt reading and discovering the membership question the hard way, resolve it first — a 513(g) Request for Information to FDA, or a De Novo / 510(k) submission built without an identified predicate, since the candidate's own frontmatter states "No K-number identified, and none should be expected" for this device.

• Requires: a formal FDA interaction — 513(g) request or submission — and, if a submission is pursued, bench and human-factors data supporting the self-application-without-a-fitter indication in the absence of a clinical study [claim 38: unverified]; an FTO position before committing submission capital [claim 19: unconfirmed]; and a viable classification pathway given no predicate is identified — [assumption A6].
• Costs: materially more calendar and capital than the exempt-route baseline in [claim 22: unconfirmed], scoped only as [assumption A6] since no connector or claim in the file prices a submission without a predicate.
• Killed by: a regulatory-counsel scoping opinion or an FDA 513(g) response concluding that no predicate and no clearly applicable regulation exist for this device's differentiating claim (the sub-bandage tension-indication question the frontmatter itself flags as "NOT identified by the Generator") — [assumption A6] resolving false, leaving no defined submission pathway to fund.

Assumption register

Every assumption cited above, with what would settle it and who could run it. These are written back to the candidate as unverified claims 51-56 — an assumption that lives only in a business case is invisible to the Verifier.

Where this case outruns the file

Every figure with no claim behind it, gathered in one place — the work items.

• The Medicare-claim-volume, price and share components of TAM (~unresolved on all three legs) — component 1 is the only one with a real primary source and it was never searched [claim 15: unconfirmed]; components 2 and 3 return unverifiable by connector design [claim 16: unconfirmed], [claim 17: unconfirmed] and no estimate was substituted for either.
• The A6583 dollar allowable itself — the single figure every other line in the money model depends on to become an economic answer, and it has never been read from a primary CMS fee schedule [claim 11: unconfirmed].
• The manufacturer's gross margin at that (unknown) allowable, after channel margin — asserted in the candidate's own deck-surfaced assumption [claim 31: unverified] but never measured.
• Calendar and capital to a first billable claim (A1, A2) — the candidate's own capital/time claim is deliberately stated without a number [claim 22: unconfirmed], and this case adds none.
• Whether the 20% coinsurance suppresses uptake (A3) — no claim in the file speaks to patient-side price sensitivity at the point of dispensing.
• Licensing economics for Route B (A4) and cash-pay willingness-to-pay for Route C (A5) — both are class-3 stakeholder-preference questions with no connector path to resolution; both stay unverifiable unless a human commissions the underlying interviews or survey.
• Submission cost and calendar for Route D absent a named predicate (A6) — the frontmatter itself states no predicate should be expected, and no claim or connector in this repo prices what a submission would cost under that condition.